ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paradigm Biopharmaceuticals Stock (ASX:PAR) 30 days 90 days 365 days Advanced Chart Get PAR alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket CapitalizationA$196.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia. Read More Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PAR Stock News HeadlinesParadigm Biopharmaceuticals to Quote New Securities on ASXAugust 25 at 12:03 PM | msn.comParadigm Launches Book-to-Film Publishing Collab; CJ Perry’s ‘Bulletproof Angel’ Set As First TitleJuly 22, 2025 | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 28 at 2:00 AM | Timothy Sykes (Ad)Paradigm Biopharmaceuticals Expands ASX Quotation with New SecuritiesJuly 22, 2025 | tipranks.com‘The Recruit’ & ‘Atypical’ Star Fivel Stewart Signs With ParadigmJuly 18, 2025 | msn.comParadigm Biopharmaceuticals Issues 7 Million Convertible NotesJuly 7, 2025 | tipranks.comParadigm Biopharmaceuticals Limited (PBIGF) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.com‘After Typhoon’ Star & UFC Champion Zhang Weili Signs With ParadigmJuly 2, 2025 | msn.comSee More Headlines PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryComputer Hardware Current SymbolASX:PAR CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,480Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$58.65 million Net Margins-89,138.58% Pretax MarginN/A Return on Equity-203.64% Return on Assets-86.16% Debt Debt-to-Equity Ratio1.01 Current Ratio7.22 Quick Ratio5.93 Sales & Book Value Annual SalesA$79.22 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares350,360,000Free FloatN/AMarket CapA$196.66 million OptionableNot Optionable Beta0.94 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (ASX:PAR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Paradigm Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access